Premium
Growth and safety of preterm infants fed a new liquid human milk fortifier
Author(s) -
Berseth Carol Lynn,
Mitmesser Susan Hazels,
Stolz Suzanne,
Harris Cheryl,
Moya Fernando,
Sisk Paula
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.589.3
Background Few studies have evaluated current generations of human milk fortifiers (HMF) in very immature infants with birth weight (BW) ≤1250 g. Objective To evaluate the benefits and safety of a new ultraconcentrated liquid HMF. Methods Preterm infants with gestational age (GA) 23.7 to 30.4 weeks and weight 530 to 1250 g at birth fed expressed and/or donor breast milk were randomized to receive powder HMF (Control, 1.1 g protein/4 sachets, Mead Johnson Nutrition ® ) or liquid HMF (LHMF, 1.8 g protein/4 vials) for 28 days. Serum prealbumin, albumin, and BUN were measured and analyzed by Kruskal‐Wallis. Weight and length growth and the occurrence of sepsis, necrotizing enterocolitis (NEC), and serious adverse events (SAEs) were monitored. Results In this 3 rd party‐blind, stratified (for GA), controlled trial, 72 of 146 infant participants weighed <1000 g. There was no difference in weight growth rate between groups (p=0.805), but achieved weight and length growth was significantly higher in LHMF vs. Control (p=0.033 and 0.03, respectively). Prealbumin, albumin, and BUN were higher in LHMF vs. Control (TABLE). There was no difference between groups for NEC or sepsis. Conclusion A new LHMF with 1.8 g protein/4 vials provides better growth than current powder HMF.